<DOC>
	<DOCNO>NCT00839072</DOCNO>
	<brief_summary>The objective study compare pharmacokinetic profile extended-release immediate-release trazodone formulation</brief_summary>
	<brief_title>Comparative Bioavailability Study Extended-release Immediate-release Trazodone Healthy Adult Volunteers</brief_title>
	<detailed_description>The bioavailability once-daily trazodone extended-release 300 mg caplets ( test product ) trazodone immediate-release 100 mg tablet administer q8h ( reference product ) compare healthy adult volunteer randomize , crossover fashion . Morning dos administer overnight fast . Blood sample collect predose pre-defined time 72 hour follow morning dose . Pharmacokinetic parameter analyze use ANOVA . Comparative bioavailability assess basis ratio least-squares mean and/or 90 % confidence interval criterion .</detailed_description>
	<mesh_term>Trazodone</mesh_term>
	<criteria>Availability entire study period willingness adhere protocol requirement evidence sign informed consent Male female volunteer , age 18 45 year inclusively BMI â‰¥20 &lt; 30 kg/m2 Minimum body weight : 60 kg Clinical laboratory value within normal range , without clinical significance Healthy accord medical history , clinical laboratory result physical examination Nonsmoker exsmoker Significant history hypersensitivity trazodone related product , severe hypersensitivity reaction drug Presence history significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug know potentiate predispose undesired effect Presence significant cardiovascular , pulmonary , hematologic , neurological , psychiatric , endocrine , immunologic , dermatologic disease Suicidal tendency , history disposition seizure , state confusion , clinically relevant psychiatric disease Use MAO inhibitor within 28 day day 1 study Presence significant heart disease disorder accord ECG Seated systolic blood pressure low 90 140 mmHg diastolic blood pressure low 50 90 mmHg screen Maintenance therapy drug , significant history drug dependency alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) Any clinically significant illness previous 28 day day 1 study Use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem , HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin , rifampin ) , previous 28 day day 1 study Females pregnant accord positive serum pregnancy test , lactate Females childbearing potential refuse use acceptable method contraception screen visit throughout study Volunteers take investigational product ( another clinical trial ) donate 50 mL blood previous 28 day day 1 study Poor motivation , intellectual problem likely limit validity consent participate study limit ability comply protocol requirement inability cooperate adequately , inability understand observe instruction physician Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc ) previous 56 day day 1 study Positive urine screen drug abuse Any history tuberculosis and/or prophylaxis tuberculosis Positive result HIV , HBsAg , antiHCV test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>bioavailability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>healthy</keyword>
	<keyword>crossover</keyword>
	<keyword>trazodone</keyword>
</DOC>